B. Metzler seel. Sohn & Co. AG Sells 47,159 Shares of Zoetis Inc. (NYSE:ZTS)

B. Metzler seel. Sohn & Co. AG cut its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 205,298 shares of the company's stock after selling 47,159 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Zoetis were worth $33,376,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Edmond DE Rothschild Holding S.A. boosted its holdings in Zoetis by 82.3% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 267,482 shares of the company's stock worth $43,581,000 after buying an additional 120,732 shares during the period. Axiom Investors LLC DE boosted its stake in shares of Zoetis by 11.9% in the fourth quarter. Axiom Investors LLC DE now owns 490,707 shares of the company's stock worth $79,951,000 after acquiring an additional 52,125 shares during the period. AIA Group Ltd boosted its stake in shares of Zoetis by 25.7% in the fourth quarter. AIA Group Ltd now owns 24,367 shares of the company's stock worth $3,970,000 after acquiring an additional 4,983 shares during the period. Wellington Management Group LLP grew its position in shares of Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Finally, Physician Wealth Advisors Inc. bought a new stake in Zoetis during the 4th quarter valued at approximately $97,000. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 over the last 90 days. Company insiders own 0.16% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research analyst reports. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $215.90.

Zoetis Trading Down 2.5 %

Shares of NYSE ZTS traded down $4.16 during trading hours on Thursday, hitting $159.34. 3,271,279 shares of the company traded hands, compared to its average volume of 2,601,809. The company's 50 day moving average price is $166.20 and its 200 day moving average price is $173.98. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The stock has a market capitalization of $71.35 billion, a price-to-earnings ratio of 29.13, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.